GlassScriptPhysician profile
Jillian Blanche Poomcharoen
NPI 1669074308
$1,039.70
in general payments reported to CMS, 2019-2025
18 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $484 · 2024: $401 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $159.00 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $132.78 | 2023-2024 | Eliquis, Camzyos |
| Exact Sciences Corporation | $103.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.92 | 2023-2024 | Jardiance |
| Pfizer INC. | $88.86 | 2023-2025 | |
| Lilly USA, LLC | $88.10 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $62.01 | 2023-2024 | Repatha |
| Lexicon Pharmaceuticals, INC. | $45.08 | 2023 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $43.98 | 2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $43.06 | 2024 | |
| Lucid Diagnostics INC. | $25.16 | 2023 | |
| Janssen Pharmaceuticals, INC | $25.00 | 2024 | Xarelto |
| Medtronic, INC. | $24.78 | 2025 | Minimed 780g |
| Glaxosmithkline, LLC. | $23.34 | 2024 | Trelegy Ellipta, Arexvy |
| Philips North America LLC | $22.98 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $22.66 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $21.88 | 2025 | Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $16.78 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Poomcharoen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.